Siga Technologies INC Restricted Cash and Cash Equivalents
Siga Technologies INC (SIGA) had Restricted Cash and Cash Equivalents of $0 as of 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-03-02
- 2022-12-31: Restricted Cash and Cash Equivalents $0.00.
- 2021-12-31: Restricted Cash and Cash Equivalents $0.00.
- 2017-12-31: Restricted Cash and Cash Equivalents $17.20M.
- 2016-12-31: Restricted Cash and Cash Equivalents $27.50M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2017-12-31 | $17.20M 10-K · filed 2018-03-06 |
| 2016-12-31 | $27.50M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |